Gilead Expands Yeztugo Access Program to 3 Million, Partnering with PEPFAR and The Global Fund
Gilead Sciences announced it will expand its global access program for Yeztugo, the company’s twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) drug, to reach 3 million people by 2028. The initiative builds on its ongoing collaboration with the U.S. State Department, the President’s Emergency Plan for AIDS Relief (PEPFAR), and The Global Fund. Deliveries have already reached nine African nations, and the program now stretches to 12 additional countries, including Haiti, Indonesia, Morocco, Rwanda, and Thailand.
The Global Fund described early uptake as “particularly strong among priority populations,” with Eswatini’s health minister pointing to rapid adoption as a marker of readiness. Expanding from 2 million to 3 million projected recipients within two years represents a 50% increase, though distributed across 21 countries and multiple production cycles. That works out to fewer than 150,000 new patients per year worldwide, progress when compared with zero last year, but still limited relative to the scale of global HIV incidence.
From a policy lens, the expansion fits squarely within the infrastructure of PEPFAR and Global Fund programs, both veterans of two decades of antiretroviral distribution. It also amounts to an implicit endorsement by U.S. public health agencies of long-acting PrEP as a frontline tool. Yet, as with earlier Gilead products like tenofovir-based oral PrEP, the constraint may not be logistics but production capacity and pricing philosophy. The real policy question now: not just how far Yeztugo can reach, but how fast Gilead intends to let it get there.
MSF Challenges Scale, Citing Minimal Allocations
Médecins Sans Frontières (MSF) pushed back hard, calling the expansion “not nearly enough.” Tom Ellman, head of MSF’s Southern Africa Medical Unit, said Eswatini, where HIV infection rates remain the world’s highest, received just 70 doses, “depleted in weeks.” A Kenyan clinic partnering with MSF received only 39. The argument isn’t about operational capacity; it’s about quantity. Ellman’s position is blunt: if Gilead can produce more, withholding doses when demand is surging is ethically indefensible. The claim implies that production capacity exceeds what Gilead currently routes through access channels.
This friction between Gilead and MSF highlights a long-running fault line in global health policy, multi-year cumulative targets versus immediate, country-level need. For national HIV programs, shipments in the dozens, not thousands, undermine public trust in rollout campaigns. Such constraints also slow pilot projects, the very ones that spark political will and community acceptance. Uptake may be “strong,” but the absolute numbers reveal a program still in its demonstration phase, not a scale-up.
If MSF’s reported numbers hold, Gilead’s collaboration with PEPFAR and The Global Fund risks the same reputational pressure that once surrounded voluntary licensing disputes over hepatitis C antivirals. Whether the company signs off on wider manufacturing partnerships, potentially with local generic producers, will decide if Yeztugo stays a boutique, donor-backed intervention or matures into a global public-sector mainstay.
Inside the Manufacturing, Regulation, and Economics of Long-Acting PrEP
Yeztugo, or lenacapavir, is given twice yearly, ideal for adherence, yet problematic for supply forecasting. Missing a shipment doesn’t delay one patient’s next dose; it delays an entire cohort. Unlike oral tenofovir-based PrEP, scalable through a generic supply chain, lenacapavir is a biologic with a complex manufacturing process. That likely explains the small allocations MSF described. It doesn’t excuse them. Industry coverage from Endpoints News flagged that very constraint, amplifying scrutiny on Gilead’s capacity planning and its ripple effects across the access landscape.
Long-acting injectables reshape the economics. Two doses secure a year of protection, so modest expansions in supply could cover far more people, if the cost per dose is controlled. Gilead’s pledge to 3 million recipients means producing roughly 6 million injections by 2028, or around 2 million annually. Even at sharply discounted prices, donor financing could still stretch into hundreds of millions of dollars. The partnership with PEPFAR and The Global Fund, then, is not only a logistics exercise but a financing one.
For investors, announcements like this defend Gilead’s image as a global health participant, not just a commercial actor. For public health agencies, they raise pragmatic concerns about whether voluntary models can ever move fast enough for biologics with high margins and complex manufacturing. Without licensing partners or local fill-finish production, Gilead risks an impossible balancing act: meet its humanitarian promise or protect its commercial margins. Not both.
Looking Ahead: Shifting Optics and Policy Pressure
The Yeztugo debate is an early test of the post-pandemic compact between major drugmakers and the global health ecosystem, one that promised speed, openness, and equitable delivery. Gilead’s move shows response to pressure, but not the acceleration MSF or recipient countries hoped for. Numbers like those from Eswatini and Kenya draw a clear line between program pilots and epidemic control. Real progress will require scale, not symbolism.
Donor agencies could force that acceleration. PEPFAR and The Global Fund have repeatedly used pooled procurement and performance-based funding to negotiate better price-volume tradeoffs. If uptake truly proves strong among target groups, they’ll have leverage to push Gilead harder. The precedent is there: when oral PrEP went generic, cost curves fell within three years, reshaping prevention budgets worldwide.
If that shift doesn’t happen, the optics turn bleak. Gilead’s U.S. commercial launch frames Yeztugo as an innovation milestone, while its global footprint remains thin. Either manufacturing is genuinely limited, or the release schedule is cautious by choice. Each scenario poses different risks, but both threaten credibility. Long-acting PrEP is moving beyond the simple generics economics of the 2010s, and Gilead’s rollout is the case study everyone’s watching.
The next half-year will show which version of this story sticks. A few new manufacturing sites or access deals could redefine it as a turning point; if nothing materializes, advocacy will sharpen and donor patience will thin. For now, this is what global health policy often looks like up close, progress, argument, and a race between goodwill and supply.
Ongoing updates to programs like Yeztugo’s are tracked at RxInfo.ai, which follows pricing and availability trends for HIV and other infectious disease treatments.
